ASGCT week is finally here and Genezen is proud to have six posters selected for display at this year’s annual meeting of the American Society of Gene and Cell Therapy, taking place in Boston, MA from May 11 – 15.
These posters showcase the depth of our technical expertise across viral vector development and manufacturing, from process optimization to analytical innovation:
- One and done: Agile CMC strategies for N-of-1 gene therapies presented by Susan D’Costa, PhD, Chief Technical & Commercial Officer
- Screening of transfection process parameters related to the complexation reaction between the transfection reagent and plasmid DNA for the impact on rAAV titer in HEK cell host presented by Eric R. Weiss PhD, Director, Process and Analytical Development
- Development of a no-extraction ddPCR-based method for residual host cell DNA quantitation and sizing in therapeutic viral vectors presented by Sheyla Mirabal, Principal Scientist, Analytical Development
- Continuous monitoring of cell and gene therapy processes in stage 3 of Process validation lifecycle presented by Vignesh Gnanavel, Manager, MSAT
- Enhancing sterile filtration efficiency and product yield in lentiviral and γ-retroviral vector manufacturing processes presented by Ishtiaque Rashid, PhD, Scientist III ‑ Downstream Process Development
- A dual optimization strategy: Refining IEX elution and eliminating citric acid to improve AAV empty and full capsid separation presented by Kaitlyn Stephens, Scientist I, Downstream PD
Each poster reflects the hands-on work our teams are doing every day to solve complex challenges and help move advanced therapies forward faster, and with greater confidence.
Click the button below to download our posters from ASGCT 2026 for further insight.
